CompletedPhase 2NCT01207687

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Studying Vestibular schwannoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Jaishri Blakeley, MD
Johns Hopkins University/Sidney Kimmel Cancer Center
Intervention
bevacizumab(biological)
Enrollment
14 enrolled
Eligibility
12 years · All sexes
Timeline
20102014

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01207687 on ClinicalTrials.gov

Other trials for Vestibular schwannoma

Additional recruiting or active studies for the same condition.

See all trials for Vestibular schwannoma

← Back to all trials